R&D Systems Inc. Tocris Bioscience Boston Biochem

Ozagrel hydrochloride

Cat. No. 1510

Ozagrel hydrochloride C13H12N2O2.HCl [74003-18-2]

Price and Availability

For Ozagrel hydrochloride pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Alternative Name: OKY 046

Chemical Name: (2E)-3-[4-(1H-Imidazol-1-ylmethyl)p­henyl]-2-propenoic acid hydrochloride

Biological Activity

Potent and selective inhibitor of thromboxane (TXA2) synthetase (IC50 = 4 nM). Does not inhibit prostacyclin (PGI2) synthetase, cyclooxygenase or PGE2 isomerase (IC50 > 1 mM). Inhibits platelet aggregation in vitro and arachidonate-induced arterial contraction in vivo.

Technical Data

M.Wt:
264.71
Formula:
C13H12N2O2.HCl
Solubility:
Soluble to 100 mM in water
Purity:
>98 %
Storage:
Store at RT
CAS No:
74003-18-2

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Select another batch:
Safety Data Sheet: View Safety Data Sheet

References

Naito et al (1983) Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets. Eur.J.Pharmacol. 91 41. PMID: 6413227.

Hiraku et al (1986) Pharmacological studies on the TXA2 synthetase inhibitor (E)-3-[p-(1H-imidazol-1ylmethyl)phenyl]-2-propenoic acid (OKY-046). Jpn.J.Pharmacol. 41 393. PMID: 3093741.

Shinagawa et al (2000) Participation of thromboxane A2 in the cough response in guinea-pigs: antitussive effect of ozagrel. Br.J.Pharmacol. 131 266. PMID: 10991919.

If you know of a relevant citation for this product please let us know.

Keywords: Ozagrel hydrochloride, supplier, Selective, thromboxane, A2, synthetase, inhibitors, Thromboxane, TP, Prostanoid, Synthases, Synthetases, prostaglandins, prostacyclins, eicosanoids, OKY046

Quick Order

Find multiple products by catalog number

divider line

Immunology Guide

Immunology Research Guide

Highlights over 150 products for immunology research. Request a copy or view PDF today.

divider line

New Therapies and Challenges in Asthma

Written by Peter J. Barnes

Asthma Poster

'New Therapies, Challenges, and Breakthroughs in Asthma' highlights key pathways and new therapies used to treat asthma, including those currently in clinical development.

divider line

Regulation of Vascular Reactivity by GPCRs

Written by J.J. Maguire and A.P. Davenport

Cardiovascular Poster

'Regulation of Vascular Reactivity by G-protein-coupled Receptors' summarizes the key GPCRs regulating vascular reactivity.

divider line

7-TM Receptor Signaling

Written by T. Kenakin et al

7-TM Poster

'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy

divider line

New Product Guide

NPG

Highlights over 130 new products added in 2012. Request a copy or view PDF today.

divider line

New Products in this Area

TC-G 1001

GPR35 agonist; more potent than zaprinast (Cat. No. 0947)

H2L 5765834

LPA1,3,5 antagonist

CYM 50308

Potent and selective S1P4 agonist

H2L5186303

Potent and selective LPA2 receptor antagonist

MEDICA 16

FFA1 (GPR40) agonist. Also inhibits ATP citrate lyase

BX 471

Potent, selective CCR1 antagonist

PF 04418948

Potent and selective EP2 receptor antagonist

Latanoprost

FP prostaglandin receptor agonist; also exhibits agonist activity at EP1 and EP3 receptors

GRI 977143

Selective LPA2 receptor non-lipid agonist

CYM 50260

Potent and selective S1P4 agonist

G-36

Selective GPR30 antagonist

Strontium chloride

Calcium sensing receptor (CaSR) agonist

CS 2100

Selective S1P1 agonist

SMANT hydrochloride

Inhibits Smoothened (Smo) accumulation

TUG 891

Potent and selective GPR120 agonist

Sign-up for new product e-alerts
divider line

20% Discount*

Potent, selective LRRK2 inhibitor

Potent LRRK2 inhibitor now available from Tocris Bioscience

Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.

* Terms & conditions